Filip Ambrozkiewicz took part in EASL 2023 Liver Cancer Summit in Portugal

Filip Ambrozkiewicz – a member of Translational Cancer Genomics laboratory – attended the EASL Liver Cancer Summit, held in April, 20th-22nd, 2023 in Estoril, Portugal, and presented his poster called “Interplay between genetic and immune factors in the tumor microenvironment and their prognostic value in hepatocellular carcinoma”.

Hepatocellular carcinoma (HCC) is a fatal disease characterized by early genetic alterations in telomerase reverse transcriptase promoter (TERTp) and β-catenin (CTNNB1) genes and by changes in immune cell landscape in the tumor microenvironment. As a novel approach, our team assessed patient survival influenced by combined presence of mutations and densities of CD3+ T-lymphocytes and CD20 B-lymphocytes. The results showed that factors both in the tumor and in its microenvironment might influence patient outcome in HCC. The best predictive values for TTR (time to recurrence) were obtained by combining data for rs2853669 and CD3+ cell densities in TC. Moreover, best predictive score for DFS (disease free survival) and OS (overall survival) were obtained by combining data for rs2853669 with CD3+ T-lymphocytes densities in TC.